Related Experiment Video

Updated: Apr 2, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

97

Haemostasis and the Need for Antithrombotics: An Introduction

John Hogwood1, Elaine Gray2

  • 1Therapeutic Reference Materials, Medicines and Healthcare Products Regulatory Agency, South Mimms, Hertfordshire, UK. john.hogwood@mhra.gov.uk.

Handbook of Experimental Pharmacology
|March 31, 2026
PubMed

Insights

Antithrombotic and antiplatelet therapies, including older and newer agents, are crucial for managing increasing global cardiovascular and thrombotic disease burdens. Continued development and monitoring of these essential medicines are vital for public health.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Public Health

Background:

  • Antithrombotic and antiplatelet agents have a long history, with many recognized as essential medicines by the WHO.
  • Global mortality and morbidity from cardiovascular diseases and thrombosis are rising.
  • Legacy drugs (heparin, warfarin) and newer agents (DOACs, antiplatelets) are critical for public health.

Purpose of the Study:

  • To provide a framework for understanding antithrombotic and antiplatelet therapies.
  • To highlight the importance of these agents in managing thrombotic diseases.
  • To set the stage for discussing new developments and monitoring requirements.

Main Methods:

  • This section is a chapter introduction, setting the context for the book.
  • It reviews the historical and current landscape of antithrombotic and antiplatelet agents.
  • It emphasizes the growing need for these therapies due to increasing disease prevalence.

Main Results:

  • The abstract does not present specific results but rather outlines the scope of the book.
  • It indicates that new therapies are continuously being developed.
  • It stresses the necessity of monitoring these therapies for safety and efficacy.

Conclusions:

  • Antithrombotic and antiplatelet agents are indispensable for global health.
  • Ongoing research and development are essential for addressing thrombotic diseases.
  • Effective monitoring is crucial for the safe and efficient use of these vital medications.

Keywords:
AnticoagulantAntithromboticsCoagulationPlateletThrombosis

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.5K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.9K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
17.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K